Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jedd Wolchok

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Cell|December 1, 2018
Putting the Immunologic Brakes on CancerJedd Wolchok
The Journal of Experimental Medicine|August 23, 2018
Refusing to TAP out: 16 new human TEIPPs identifiedMathieu Gigoux, Jedd Wolchok
Pigment Cell & Melanoma Research|March 30, 2012
Alan HoughtonJedd Wolchok, Paul Chapman
Science (New York, N.Y.)|November 28, 2015
IMMUNOTHERAPY. Could microbial therapy boost cancer immunotherapy?Alexandra Snyder, Eric Pamer, Jedd Wolchok
Cancer Cell|May 12, 2023
RECISTv1.1 progression in oncology: Shades of grayBrian Topp, Alexandra Snyder, Jedd Wolchok
Current Opinion in Genetics & Development|March 25, 2014
The importance of animal models in tumor immunity and immunotherapySadna Budhu, Jedd Wolchok, Taha Merghoub
Journal of Cutaneous Pathology|February 27, 2004
Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanomaKlaus J Busam, Jedd Wolchok, Achim A Jungbluth, et al.
The New England Journal of Medicine|April 5, 2013
Hepatotoxicity with combination of vemurafenib and ipilimumabAntoni Ribas, F Stephen Hodi, Margaret Callahan, et al.
Endocrine-Related Cancer|March 11, 2014
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institutionMabel Ryder, Margaret Callahan, Michael A Postow, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 14, 2022
Immune-Related Adverse Events Among COVID-19-Vaccinated Patients With Cancer Receiving Immune Checkpoint BlockadeAdam J Widman, Bevin Cohen, Vivian Park, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Cell|December 1, 2018
Putting the Immunologic Brakes on CancerJedd Wolchok
The Journal of Experimental Medicine|August 23, 2018
Refusing to TAP out: 16 new human TEIPPs identifiedMathieu Gigoux, Jedd Wolchok
Pigment Cell & Melanoma Research|March 30, 2012
Alan HoughtonJedd Wolchok, Paul Chapman
Science (New York, N.Y.)|November 28, 2015
IMMUNOTHERAPY. Could microbial therapy boost cancer immunotherapy?Alexandra Snyder, Eric Pamer, Jedd Wolchok
Cancer Cell|May 12, 2023
RECISTv1.1 progression in oncology: Shades of grayBrian Topp, Alexandra Snyder, Jedd Wolchok
Current Opinion in Genetics & Development|March 25, 2014
The importance of animal models in tumor immunity and immunotherapySadna Budhu, Jedd Wolchok, Taha Merghoub
Journal of Cutaneous Pathology|February 27, 2004
Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanomaKlaus J Busam, Jedd Wolchok, Achim A Jungbluth, et al.
The New England Journal of Medicine|April 5, 2013
Hepatotoxicity with combination of vemurafenib and ipilimumabAntoni Ribas, F Stephen Hodi, Margaret Callahan, et al.
Endocrine-Related Cancer|March 11, 2014
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institutionMabel Ryder, Margaret Callahan, Michael A Postow, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 14, 2022
Immune-Related Adverse Events Among COVID-19-Vaccinated Patients With Cancer Receiving Immune Checkpoint BlockadeAdam J Widman, Bevin Cohen, Vivian Park, et al.
Pageof 4